Euroespes (XMAD:EEP) Inventory-to-Revenue : 0.33 (As of Dec. 2022)

View and export this data going back to 2011. Start your Free Trial

What is Euroespes Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Euroespes's Average Total Inventories for the quarter that ended in Dec. 2022 was €0.54 Mil. Euroespes's Revenue for the six months ended in Dec. 2022 was €1.64 Mil. Euroespes's Inventory-to-Revenue for the quarter that ended in Dec. 2022 was 0.33.

Euroespes's Inventory-to-Revenue for the quarter that ended in Dec. 2022 declined from Jun. 2022 (0.35) to Jun. 2022 (0.33)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Euroespes's Days Inventory for the six months ended in Dec. 2022 was 639.94.

Inventory Turnover measures how fast the company turns over its inventory within a year. Euroespes's Inventory Turnover for the quarter that ended in Dec. 2022 was 0.29.

Euroespes Inventory-to-Revenue Historical Data

The historical data trend for Euroespes's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Euroespes Inventory-to-Revenue Chart

Euroespes Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Inventory-to-Revenue

Get a 7-Day Free Trial

0.20

0.16

0.15

0.16

Euroespes Semi-Annual Data
	Dec12	Jun13	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22
Inventory-to-Revenue	Get a 7-Day Free Trial															0.26	0.35	0.29	0.35	0.33

Competitive Comparison of Euroespes's Inventory-to-Revenue

For the Diagnostics & Research subindustry, Euroespes's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Euroespes's Inventory-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Euroespes's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Euroespes's Inventory-to-Revenue falls into.

Euroespes Inventory-to-Revenue Calculation

Euroespes's Inventory-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

	Inventory-to-Revenue (A: Dec. 2022 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2021 )	+	Total Inventories (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )
=	( (0.55	+	0.475)	/	2 )	/	3.298
=	0.5125					/	3.298
=	0.16

Euroespes's Inventory-to-Revenue for the quarter that ended in Dec. 2022 is calculated as

	Inventory-to-Revenue (Q: Dec. 2022 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Jun. 2022 )	+	Total Inventories (Q: Dec. 2022 ))	/	count )	/	Revenue (Q: Dec. 2022 )
=	( (0.605	+	0.475)	/	2 )	/	1.64
=	0.54					/	1.64
=	0.33

Euroespes (XMAD:EEP) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Euroespes's Days Inventory for the six months ended in Dec. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2022 )	/	Cost of Goods Sold (Q: Dec. 2022 )	*	Days in Period
	=	0.54	/	0.154	*	365 / 2
	=	639.94

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Euroespes's Inventory Turnover for the quarter that ended in Dec. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2022 )	/	Average Total Inventories (Q: Dec. 2022 )
	=	0.154	/	0.54
	=	0.29

Euroespes Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Euroespes's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Euroespes (XMAD:EEP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Euroespes SA (XMAD:EEP) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Santa Marta de Babio, Bergondo, La Coruna, ESP, 15165

Website

http://www.euroespes.com

Euroespes SA is a biomedical research center offering medical, research, medical informatics and bioinformatics services. It offers medicine and personalized treatment for central nervous system disorders and researches genomic medicine. Other services offered by the company include genomics, digital diagnosis, diagnostic imaging, neuro-psychology, neuro-ophthalmology, nursing, epigenetics, clinical analysis and otorhinolaryngology.